Compare BioNTech SE - ADR (BNTX) vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $41.16. The key difference: YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | QDTY | |
|---|---|---|
Market Cap | $22.86B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $119.34 | $46.71 |
52-Week Low | $83.89 | $36.57 |
Enterprise Value | $6.53B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
QDTY trades at $40.43, down 1.84% today amid bearish technical signals. The stock faces selling pressure with moving averages indicating a downtrend, while oscillators remain neutral. Recent weekly dividend announcements from YieldMax ETFs highlight the fund's distribution strategy, though key financial ratios are currently unavailable for fundamental assessment.
The outlook remains cautious with technical indicators pointing to continued weakness. Investment opportunity hinges on the ETF's ability to maintain consistent distributions, while risks include market volatility and the absence of clear valuation metrics. Investors should await updated financial disclosures for fundamental clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →
